MiMedx Group enters into distribution agreement with Medtronic and SpinalGraft Technologies

MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has entered into a distribution agreement with Medtronic, Inc. and SpinalGraft Technologies, LLC ("SGT"), a wholly-owned subsidiary of Medtronic. Through the agreement, MiMedx will provide its PURION® processed allograft products to Medtronic to be marketed by SGT for spinal applications.

The MiMedx PURION® processed allograft products distributed to Medtronic will be private-labeled. SGT will promote, market and sell the private-labeled allografts to its customers and end-users through-out the United States.

Parker H. Petit, MiMedx Chairman and CEO, said, "This agreement is a significant milestone for MiMedx in expanding our customer base and broadening the breadth of physicians and patients with access to our PURION® processed allografts. By partnering with Medtronic, many additional physicians and patients can be served through the extensive distribution arm and presence that Medtronic has in the spinal surgery market."

The $3.1 billion Spine business segment of Medtronic is developing many of the new standards of care in spinal and musculoskeletal therapies. Medtronic collaborates with world-renowned surgeons, researchers, and innovative partners to offer a broad range of state-of-the-art products and technologies that return patients to normal active lives more quickly, and treat a variety of musculoskeletal, neurological, orthopedic, and spinal conditions.

"We are very excited about our relationship with Medtronic," said Bill Taylor, MiMedx President and COO. "Medtronic has done an extraordinary job in serving the needs of practicing physicians. With the growing demand for an offering that can deliver the outcomes achieved by our PURION® processed allografts, it is critical to align with a partner that has unparalleled respect among physicians and extensive relationships in this sector of healthcare."

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Medtronic. (2019, June 19). MiMedx Group enters into distribution agreement with Medtronic and SpinalGraft Technologies. News-Medical. Retrieved on November 21, 2024 from https://www.news-medical.net/news/20131001/MiMedx-Group-enters-into-distribution-agreement-with-Medtronic-and-SpinalGraft-Technologies.aspx.

  • MLA

    Medtronic. "MiMedx Group enters into distribution agreement with Medtronic and SpinalGraft Technologies". News-Medical. 21 November 2024. <https://www.news-medical.net/news/20131001/MiMedx-Group-enters-into-distribution-agreement-with-Medtronic-and-SpinalGraft-Technologies.aspx>.

  • Chicago

    Medtronic. "MiMedx Group enters into distribution agreement with Medtronic and SpinalGraft Technologies". News-Medical. https://www.news-medical.net/news/20131001/MiMedx-Group-enters-into-distribution-agreement-with-Medtronic-and-SpinalGraft-Technologies.aspx. (accessed November 21, 2024).

  • Harvard

    Medtronic. 2019. MiMedx Group enters into distribution agreement with Medtronic and SpinalGraft Technologies. News-Medical, viewed 21 November 2024, https://www.news-medical.net/news/20131001/MiMedx-Group-enters-into-distribution-agreement-with-Medtronic-and-SpinalGraft-Technologies.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
DreaMed Diabetes and Medtronic enter strategic collaboration